Jane Nicholson

CEO

Jane Nicholson is our CEO. With a robust background in both the commercial and non-profit sectors, Jane has been instrumental in shaping, driving, and leading WMUK towards achieving its strategic goals. She joined WMUK in March 2021 and has been passionate about improving patient outcomes for those with Waldenstrom’s macroglobulinaemia through the WM Registry & WMUK.

Experience and Leadership
Jane’s experience in the charity sector includes focusing on enhancing patient care, supporting research initiatives, and advocating for better treatment options. Under her leadership, WMUK has launched several key initiatives including research programmes, production of original education materials for healthcare professionals, and the rollout of the WMUK Support Line.

Contributions and Impact
Jane has spearheaded fundraising efforts and fostered collaborations to drive forward WMUK’s mission. Her commitment to the organisation is evident in her efforts to engage with the community and improve the lives of those affected by WM.

Collaborative Initiatives and Services
Jane’s leadership has facilitated partnerships and alliances, such as the strategic collaboration with Dendrite Clinical Systems to enhance research. Her work ensures that WMUK remains a vital resource for patients, providing support, information, and advocating for better treatment and care standards.

Charlotte Bloodworth

Professional Background and Experience:
Charlotte Bloodworth is a highly experienced Advanced Nurse Practitioner (ANP) specialising in Haematology at University Hospital of Wales, Cardiff, part of NHS Wales. She has dedicated her career to providing exceptional care to patients with haematological conditions, working within the Cardiff and Vale University Health Board. Charlotte’s role involves managing patient care from diagnosis through treatment, ensuring the highest standards of practice in haematology.

Charlotte qualified as a registered nurse at the University of Nottingham in 1995. She has extensive experience within haematology since joining the Cardiff team in 2003. She has worked on the general Haematology ward, the Bone Marrow Transplant Unit and the Day Unit before becoming Lymphoma Specialist Nurse in 2009. And has worked as an Advanced Nurse Practitioner in Lymphoma since 2017.

Educational Qualifications:
Charlotte has undertaken extensive training and education to achieve her current role as an Advanced Nurse Practitioner. Her qualifications include advanced clinical practice training specific to haematology, supported by ongoing professional development to stay abreast of the latest advancements in the field.

Achievements and Recognitions:
Throughout her career, Charlotte has been recognized for her contributions to haematology. She has been involved in various initiatives aimed at improving patient care and outcomes, including innovative workforce planning within the haematology department (Lymphoma Action) (NHS Wales Executive). Charlotte’s work in developing and implementing patient-focused care models has been instrumental in enhancing the quality of haematological services at NHS Wales.

Charlotte Bloodworth was runner-up for the Royal College of Nursing (RCN) Wales Innovation in Nursing Award in 2018.

Affiliations and Memberships:
Charlotte is a member of medical advisory group for Lymphoma Action Charity, National Non-Hodgkin Lymphoma Audit (NNHLA) Clinical Reference Group, & actively involved in other professional organisations related to haematology and advanced nursing practice. Her affiliations include participation in national and regional haematology groups, contributing to the development of clinical guidelines and standards of care (NHS Wales Executive) (Cardiff and Vale University Health Board).

Personal Anecdotes and Motivations:
Charlotte’s commitment to haematology stems from a deep-seated passion for patient care and advocacy. Her personal experiences and interactions with patients inspire her to continually seek ways to improve the healthcare system and provide compassionate, evidence-based care.

Contributions to NHS Wales:
At NHS Wales, Charlotte has played a crucial role in advancing haematological care. She has led numerous projects aimed at optimizing patient pathways, enhancing diagnostic and treatment protocols, and integrating research into clinical practice (Lymphoma Action) (NHS Wales Executive) (Cardiff and Vale University Health Board). Her leadership and expertise have significantly contributed to the haematology department’s reputation for excellence.

Media and Online Presence:
Charlotte actively shares her expertise and insights through various platforms, including professional networks and healthcare forums. She has contributed to publications and presentations that highlight best practices in haematology and advanced nursing, including videos on Haemotolgy Patient Support, webinars for WMUK, and podcasts for Lymphoma Action.

Kat Tucker

Deputy CEO

Kat joined WMUK in 2020. She supports Jane in the smooth running of the charity, whilst leading on the charity’s patient information, and measuring the impact of the charity’s work, identifying areas where we can further help patients and families

Lorena Silverton

Database and Governance Manager

Lorena joined WMUK in the summer of 2023. With extensive experience in helping small charities to grow by harnessing the power of data, Lorena helps to ensure the charity runs smoothly behind the scenes.

Alison McKinney

Chief Nursing Officer

Alison McKinney is the Chief Nursing Officer at WMUK, where she joined in August 2022. She set up the WMUK Support Line and is now responsible for clinical support and education, including organising Nurse Study Days and bridging the gap between patients and clinicians to raise awareness and improve care and outcomes for patients with Waldenstrom’s macroglobulinaemia (WM).

Education and Training
Alison McKinney is a fully qualified Registered Nurse (RCN) with significant experience.

Clinical Practice and Specialisation
Before joining WMUK, Alison worked as a clinical nurse specialist. She has experience in both the public and private hospital settings and the charity sector, caring for a range of cancer diagnoses and treatment modalities.

Contributions and Impact
At WMUK, Alison’s contributions include setting up and managing the Support Line, which provides vital assistance to patients and their families. She is actively involved in educational initiatives including Nurse Study Days, & the development of WM-related educational materials for Continuing Professional Development (CPD), to enhance the knowledge and skills of healthcare professionals in the treatment and care of WM patients.

Collaborative Initiatives and Services
Alison plays a key role in improving WM patient outcomes through her work. She is dedicated to raising WM awareness and bridging the gap between patients and healthcare professionals.

Beth Webster

Clinical & Community Support Nurse

Beth is a fully qualified nurse, with 12 years of experience, with four years working directly in haematology. From this time she gained significant experience working with WM patients, specifically on a haematology day unity and as a Lymphoma Clinical Nurse Specialist. Her role also encompasses engaging and supporting the WM community, from connecting patients and loved ones to the right kinds of information and support they need, to how they can also get involved in supporting WMUK too.

Dr Shirley D’Sa

A prominent figure in the haematological community, Dr. Shirley D’Sa MD, FRCP, FRCPath helped found WMUK, and is dedicated to improving care and support for patients with Waldenström’s Macroglobulinaemia. Through her efforts, she has helped bridge the gap between health professionals and patients, striving to overcome barriers in patient care.

Dr. D’Sa’s dedication to advancing haematology and improving patient outcomes makes her a respected leader in her field. Her work not only impacts her patients and their families but also sets new benchmarks in research and clinical practice globally.

Education and Training
Dr. Shirley D’Sa MD, FRCP, FRCPath began her medical education at St George’s Hospital Medical School, University of London, graduating in 1990. Her postgraduate training included a pivotal year in Haematology and Oncology at the prestigious Royal Marsden and Charing Cross Hospitals. After earning her MRCP, she specialised in Haematology at University College Hospital London (UCLH) starting in 1995.

Research and Specialisation
Following her FRCPath qualification in 2000, Dr. D’Sa pursued an MD research degree at UCL. Her research focused on studying immune recovery in multiple myeloma patients using advanced flow cytometry and molecular techniques, after a novel donor stem cell transplantation. She was appointed as a Consultant Haematologist at UCLH in 2002, focusing primarily on myeloma.

Leadership and Clinical Focus
In 2004, Dr. D’Sa established the UCLH Centre for Waldenström’s Macroglobulinaemia and Related Conditions. This centre has become the largest dedicated facility for WM in Europe, known for its comprehensive approach to this rare cancer and related conditions like Cold Agglutinin Disease and Cryoglobulinaemia. Her innovative treatments in these areas have significantly influenced global standards.

Collaborative Initiatives and Services
Dr. D’Sa’s collaboration with Professor Michael Lunn has led to the creation of two national services at UCLH: the Neurohaematology Service and the Joint POEMS Service. These services are renowned for managing complex immunologically driven conditions and rare diseases linked to myeloma-like cells, respectively.

Academic Contributions and Community Involvement
Dr. D’Sa holds the position of honorary associate professor at the UCL Cancer Institute. She is deeply involved in clinical trials, serving as the UK Chief Investigator for numerous studies focusing on Waldenström’s Macroglobulinaemia and Cold Agglutinin Disease. She also plays a crucial role in biobanking and genomic studies that aim to enhance our understanding of lymphoid malignancies.

General Medical Council
UCLH
Publications

Dr Helen Mcarthy, Consultant Haematologist

Dr Helen McCarthy

Dr. Helen McCarthy FRCP PhD FRCPath is a Consultant Haematologist at Royal Bournemouth Hospital, where she leads a team of scientific and clinical researchers dedicated to improving survival rates and the quality of life for patients with blood cancers. She is also a member of the WMUK Medical Advisory Board and a trustee of WMUK.

Education and Training
Dr. McCarthy trained at the University of Cambridge, where she graduated with a first-class honors degree. She continued her studies at Imperial College London before completing her specialist haematology training at University College London Hospital.

Clinical Practice and Specialisation
Dr. McCarthy specializes in the treatment of chronic lymphoid malignancies, including multiple myeloma, chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinaemia. She has been instrumental in numerous clinical trials, focusing on innovative treatments and therapies, and has significantly contributed to the field of haematology.

Research and Contributions
Her research interests include epigenetic factors influencing prognostic outcomes in acute myeloid leukemia. Dr. McCarthy contributed to 18 publications, including guidelines on the diagnosis and management of Waldenström macroglobulinaemia, and has received over 1,000 citations, including in the Oxford Guide to Clinical Haematology. Her work on drugs such as Ibrutinib and Chlorambucil has been pivotal in advancing treatment options for patients.

Awards and Recognitions
In 2017, Dr. McCarthy received the Inspirational Woman in Science and Technology award at the Dorset Venus Awards, highlighting her dedication to scientific excellence and her impact on the field of haematology.

Collaborative Initiatives and Services
At Royal Bournemouth Hospital, Dr. McCarthy’s leadership has fostered a culture of innovation and collaboration, contributing to the hospital’s reputation as a center of excellence for haematological research and patient care.

Links & References for Dr. Helen McCarthy

Works for: The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
Member of Organisations:
- Royal College of Physicians
- Royal College of Pathologists
- British Society of Haematology
- WMUK Medical Advisory Board
- WMUK Trustee
Occupation: Consultant Haematologist
Alumni Of: University of Cambridge, Imperial College London, University College London Hospital
Qualifications: FRCP, PhD, FRCPath
Main Contact URL:
- Bournemouth University Profile
Main Contact Email:
Other References

Jane Kidd

Jane Kidd is a Trustee for WMUK, & also a Waldenstrom’s Macroglobulinaemia patient. She has operated as an independent Consultant and Non-Executive Director for the past 7 years, working to build board-level strategies that help transform organisations, teams and brands, elevating business performance, and driving growth and transformation.

Jane is a highly experienced leader with 30 years experience working in global Pharma companies, holding global, regional, and country executive positions in strategic marketing, market access, healthcare solutions and as a managing director. She has operated as an independent Consultant and Non-Executive Director for the past 7 years, working to build board-level strategies that help transform organisations, teams and brands, elevating business performance, and driving growth and transformation.

Dr Harriet Scorer

Dr. Harriet Scorer MB BS FFPM is a prominent figure in the Over-The-Counter (OTC) pharmaceutical industry with over 25 years of experience. Diagnosed with Waldenström’s macroglobulinaemia over 20 years ago, she is a qualified doctor specialising in gynaecology and runs her own healthcare consultancy business.

Education and Training
Dr. Scorer holds a Fellowship from the Faculty of Pharmaceutical Medicine, a Diploma in Pharmaceutical Medicine from the University of Wales, Cardiff, an MB BS in Medicine from Charing Cross Hospital Medical School, and an MA in Medical Sciences from Trinity College, Cambridge.

Clinical Practice and Specialisation
Dr. Scorer has extensive experience in the OTC pharmaceutical industry, where she has served as a medical director at a global OTC company. Her work has spanned several critical areas including medical affairs, new product development (NPD), product launches, medical devices, pharmacovigilance, and claims development.

Research and Contributions
Dr. Scorer has contributed to research on numerous topics including Ibrutinib, Chlorambucil, chronic lymphocytic leukemia, and Waldenström’s macroglobulinaemia. Her involvement with the UK Medicines Commission and as an advisor to the Health Select Committee showcases her significant influence on the pharmaceutical and healthcare industries.

Leadership and Recognition
She is a trustee and a member of the WMUK Medical Advisory Board, where she contributes to strategic decisions and research initiatives. Her leadership roles have also included offering consultancy to the UK government and various organizations ranging from large international corporations to SMEs.

Collaborative Initiatives and Services
Dr. Scorer’s consultancy firm, OTCexperts, specializes in offering medical and regulatory healthcare solutions. Her breadth of experience and commitment to advancing healthcare have established her as a respected leader in her field.

Organisations:
- Medicines Commission
- Advisor to the Health Select Committee
Occupation: Consultant, Medical Director, Gynaecologist
Qualifications: FRCP, PhD, FRCPath
Links:

Dr Dima El-Sharkawi

Chair of WMUK’s Clinical Advisory Board

Dr. Dima El-Sharkawi MB BS MA PhD MRCP FRCPath is a distinguished Consultant Haematologist at The Royal Marsden NHS Foundation Trust, renowned for her expertise in haematology, particularly in the treatment and research of chronic lymphoid malignancies.

Her clinical focus encompasses a wide range of lymphoid malignancies, including Hodgkin and non-Hodgkin lymphoma, Waldenström Macroglobulinaemia, and chronic lymphocytic leukaemia (CLL). Dr El-Sharkawi has been instrumental in numerous clinical trials, exploring innovative treatments and therapies that continue to impact patient care positively.

Education and Training
Dr. El-Sharkawi began her medical journey at the University of Cambridge, where she graduated with a First Class Honours degree. She continued her studies at Imperial College London before undertaking specialist haematology training at University College London Hospital.

Research and Specialisation
Her research interests are deeply rooted in the epigenetic factors influencing prognostic outcomes in acute myeloid leukaemia, a focus she developed during her time at the UCL Cancer Institute. This work led to her receiving the prestigious European Hematology Association (EHA) Clinical Research Fellowship in 2017, underscoring her commitment to advancing haematological research.

Clinical Practice and Specialisation
Dr. El-Sharkawi’s clinical focus encompasses a wide range of lymphoid malignancies, including Hodgkin and non-Hodgkin lymphoma, Waldenström Macroglobulinaemia, and chronic lymphocytic leukaemia (CLL). At The Royal Marsden, she is an integral part of the haematological malignancy diagnostic services, where her expertise supports the development of targeted treatment strategies for complex cases.

Contributions and Impact
Dr. El-Sharkawi has been instrumental in numerous clinical trials, exploring innovative treatments and therapies that continue to positively impact patient care. Her work reflects a profound dedication to her field and contributes significantly to the broader medical community’s understanding of haematological disorders.

Links & References

Works for: The Royal Marsden NHS Foundation Trust

Occupation: Consultant Haematologist
Alumni Of: University of Cambridge, Imperial College London, University College London Hospital
Main Contact URL:
- Royal Marsden Profile
- The Royal Marsden NHS Foundation Trust
  EHA Clinical Research Fellowship
  Private Healthcare Information Network
  Bupa
  Twitter

Dr Roger Owen

Dr. Roger Owen, MD, MRCP, FRCPath, serves as a Consultant in Clinical Haematology and Haematopathology at the St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust. His academic and clinical journey began with a medical degree from the University of Wales College of Medicine in 1988, followed by gaining his MRCP from the Royal College of Physicians, London, and his FRCPath from the Royal College of Pathologists, London.

Education and Training
Dr. Roger Owen received his medical degree from the University of Wales College of Medicine in 1988. He then earned his MRCP from the Royal College of Physicians, London, and his FRCPath from the Royal College of Pathologists, London.

Research and Specialisation
Dr. Owen has dedicated a significant portion of his career to the study and treatment of Waldenström’s macroglobulinaemia (WM), myeloma, and related plasma cell disorders. His pioneering work includes the development of a disease-specific assay for WM and leading roles in national and international treatment guidelines for these conditions. With over 100 original papers published in prestigious journals, his contributions to haematology extend beyond patient care to shaping clinical practices and research in WM, myeloma, and plasmacytoma.

Leadership and Clinical Focus
Dr. Owen’s leadership roles include developing national and international treatment guidelines for WM and related conditions. His work has been recognized with the prestigious Waldenström’s Award at the 9th International Workshop on Waldenström’s Macroglobulinaemia in Amsterdam. In addition to his clinical responsibilities, Dr. Owen actively contributes to the advancement of haematology through his involvement in national clinical trial groups and as a member of WMUK’s Clinical Advisory Committee & Research Committee.

Contributions and Impact
As a Consultant Haematologist, Dr. Owen has a particular interest in the diagnosis, treatment, and disease monitoring in patients with Myeloma, MGUS, Waldenström’s macroglobulinaemia, and marginal zone lymphoma. He has published extensively in renowned journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood.

Collaborative Initiatives and Services
Dr. Owen has collaborated extensively with various professionals and organizations. Beyond his clinical and research endeavors, he serves as a Trustee of the Friends of Leeds Centre for Leukaemia, Lymphoma, and Myeloma since 2007.

Works for: St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust
Member of Organisations:
- WMUK’s Clinical Advisory Committee & Research Committee
- Friends of Leeds Centre for Leukaemia, Lymphoma, and Myeloma
Occupation: Consultant Haematologist
Alumni Of: University of Wales College of Medicine (now merged with Cardiff)
Qualifications: MD, MRCP, FRCPath
Links:
- Friends of Leeds Centre for Leukaemia, Lymphoma, and Myeloma
- Leeds Teaching Hospitals NHS Trust Profile
- Bupa Consultant Profile
- Facebook Post
- HME Forum Profile (for healthcare professionals only)

Prof Guy Pratt

Professor Guy Pratt is a Consultant Haematologist at University Hospitals Birmingham NHS Foundation Trust and a Professor of Haematology (Haemato-Oncology) at the University of Birmingham. He also serves as the Deputy Director of the Cancer Research UK Clinical Trials Unit, where he oversees haematology trials.

Education and Training
Professor Pratt trained at Cambridge University, qualifying in 1989. Following his junior doctor training in London, he specialized as a registrar in Haematology in Liverpool and Leeds, completing an MD thesis on multiple myeloma in Leeds.

Clinical Practice and Specialisation
Since 2001, Professor Pratt has been a Consultant Haematologist in Birmingham. His main clinical and research interests include multiple myeloma, chronic lymphocytic leukaemia (CLL), Waldenström’s macroglobulinaemia, and related plasma cell disorders. At University Hospitals Birmingham, he plays a crucial role in treating these conditions and developing targeted treatment strategies.

Research and Contributions
Professor Pratt has a strong research background, particularly in the tumour microenvironment in multiple myeloma and the use of mass spectrometry to measure myeloma proteins. He has been involved in numerous clinical trials both locally and nationally and has a prolific publication record, with over 380 papers and systematic reviews. He was the clinical lead for the 2016 NICE myeloma guidelines and has held several national roles, including BSH guideline lead for Haemato-Oncology and chair of the BSH science and publication committee.

Membership and Recognition
He is a member of various professional organizations, including the British Society for Haematology (BSH), UK Myeloma Society, and International Myeloma Working Group. He is also a trustee of Cure Leukaemia and has been actively involved in patient advocacy and educational initiatives for healthcare professionals.

Collaborative Initiatives and Services
Professor Pratt’s work includes examining the metabolic changes in multiple myeloma and its precursor states, developing novel therapies, and enhancing clinical trial frameworks to advance haematological research and patient care.

University Hospitals Birmingham

Works for: University Hospitals Birmingham NHS Foundation Trust, University of Birmingham
Member of Organisations:
- British Society for Haematology (BSH)
- UK Myeloma Society
- Cure Leukaemia (Trustee)
- UK Myeloma Research Alliance
- International Myeloma Working Group
Occupation: Consultant Haematologist, Professor of Haematology (Haemato-Oncology), Deputy Director of the Cancer Research UK Clinical Trials Unit
Alumni Of: University of Cambridge
Qualifications: MA, MBBChir, MD, FRCP, FRCPath
Main Contact URL:

Charles Lilley

Background and Early Career Charles Lilley began his career in the NHS in 1972, starting as a gardener and grave-digger in a psychiatric hospital. His dedication and talent quickly saw him progress to becoming an NHS management trainee. Over the years, he held various posts within the NHS, culminating in his role as IT Manager at Great Ormond Street Hospital for Children

Public Sector and Consulting Contributions Charles played a significant role in public sector modernization. He was involved in the Integrated Service Teams initiative within the Cabinet Office and led a review of the Social Exclusion Unit for former Prime Minister Tony Blair. Additionally, he collaborated with Matthew Taylor on an Institute of Public Policy Research study focused on Public-Private Partnerships. These roles underscore his commitment to improving public services through strategic and technological innovations.

Advocacy for Patient Involvement A passionate advocate for greater patient involvement in healthcare, Charles promotes the idea that patients should have access to and be custodians of their own health information. He believes in the potential of technology to enhance patient care, from surgical robots to advanced medical devices. His vision includes empowering individuals to manage their own health conditions effectively through technology.

Entrepreneurial Ventures and Health IT Expertise Charles’s entrepreneurial spirit has led him to significant roles in both public and private sectors. His extensive experience includes working with major consulting organizations like KPMG and Deloitte & Touche, holding a senior management role in a UK FTSE 100 software company, and founding and running his own companies. His specialties include market analysis, business development, sales, corporate development, investment and funding, growth and exit strategies.

Professional Insights and Market Trends With nearly 40 years in healthcare and IT, Charles offers unique insights into the dynamics of the health IT market. His extensive experience allows him to provide valuable analysis and identify market trends and opportunities. His roles as a director and senior executive of various companies further highlight his expertise in healthcare informatics and technology.

Links for Further Information

Joy Ellery

Joy Ellery is a Patient Safety Partner at The Royal Marsden Hospital and a member of the WMUK Research Committee. With extensive experience in the NHS, Joy has been dedicated to enhancing patient safety and care.

Experience and Leadership
Joy’s career includes significant roles such as Director of Knowledge, Governance, and Communications at Lewisham and Greenwich NHS Trust from 2005 to 2014. She also served as a Lay Member (PPI) at Southwark Clinical Commissioning Group from 2015 to 2022 and at South East London Clinical Commissioning Group since 2022. Additionally, she has been self-employed as a Patient Safety Partner since 2023.

Contributions and Impact
At WMUK, Joy actively participates in the Research Committee, contributing her extensive knowledge to advance research and improve patient care for those with Waldenstrom’s macroglobulinaemia. Her role at The Royal Marsden involves implementing patient safety measures and fostering an environment of compassionate care.

Collaborative Initiatives and Services
Joy’s work bridges the gap between patients and healthcare providers, ensuring patient voices are integrated into safety protocols and care strategies.

Links & References

Works for: The Royal Marsden Hospital
Member of Organisations: WMUK Research Committee
Occupation: Patient Safety Partner
Other Links:

Professor Sam Salek

Professor Sam Salek RPh PhD FFPM GFMD FRPS FESCP MCMS, is a distinguished Professor of Pharmacoepidemiology serving in the School of Life and Medical Sciences at the University of Hertfordshire, where he leads the Public Health & Patient Safety research group. He also holds the position of Director at the Institute for Medicine Development in Cardiff.

Education and Training
Professor Salek completed his undergraduate degree in Pharmacy at the University of Oklahoma, followed by a PhD at Cardiff University. His academic journey laid a solid foundation for his extensive contributions to Health Economics, Patient-reported Outcomes (PRO), and Pharmaceutical Regulatory Science.

Research and Specialisation
Professor Salek has contributed to over 250 publications, recieved over 7000 citations, and authored journal articles and abstracts, significantly advancing the practical applications of patient-reported outcome (PRO) measures in clinical decision-making and policy. His research interests include the development, evaluation, and application of instruments to assess patient-reported outcomes and health-related quality of life (HRQoL), as well as pharmacoeconomics and benefit-risk assessment of medicines.

Awards and Recognitions
He has received numerous awards, including the Medal of the Czech Medical Association of Jan Evangelista Purkyne and the Fellowship Award from the European Society of Clinical Pharmacy. As a Fellow of the Royal College of Physicians, the Royal Pharmaceutical Society, and the European Society of Clinical Pharmacy, his contributions have been widely recognized.

Contributions and Impact
Professor Salek has been instrumental in the development of undergraduate and postgraduate programs, including the modernization of the Postgraduate Course in Pharmaceutical Medicine and the establishment of the MSc in International Pharmaeconomic & Health Economics. He is also the founder of the Integrated Master of Regulatory Science program.

Collaborative Initiatives and Services
His work bridges various domains of research and clinical practice, focusing on improving patient outcomes and enhancing healthcare quality through innovative research and education.

Works for: University of Hertfordshire, Institute for Medicine Development in Cardiff
Member of Organisations:
- Royal College of Physicians
- Fellow of the Faculty of Pharmaceutical Medicine (FFPM)
- Global Fellows in Medicines Development (GFMD)
- Fellow of Royal Pharmaceutical Society
- Fellowship of European Society of Clinical Pharmacy
Occupation: Professor of Pharmacoepidemiology, Director
Alumni Of: University of Oklahoma, Cardiff University
Qualifications:
- Registered Pharmacist (RPh)
More Links:

Dr Karen Facey

Dr. Karen Facey is a Chartered Statistician and an Honorary Member of the Faculty of Public Health. She works internationally as an Evidence-Based Health Policy Consultant, specialising in health technology assessment (HTA).

Career and Recognition

In 2014, Dr. Facey was recognized as one of the top 100 practicing scientists in the UK. Her career began as a statistician in the pharmaceutical industry and medicines regulation before transitioning to HTA, a multidisciplinary policy analysis that examines the medical, social, ethical, and economic impacts of health interventions. She has extensive experience as a statistician in medicines development and regulation, having served on the UK regulatory committee for the safety of medical devices for over eight years.

Leadership and Contributions

In 2000, Dr. Facey established the Health Technology Board for Scotland, the first national HTA body in Scotland. For over a decade, she led the development of the resource allocation formula for health boards in Scotland. She also chaired the government committee that established the new funding formula for the NHS (NRAC).

Publications and Patient Involvement

Dr. Facey was the lead editor of the book on patient involvement in HTA, published in 2017, and has played a significant role in developing patient involvement processes in health technology assessment.

She has contirbuted to over 60 publications & has recieved over 2,800 citations

Research and Specialisation

Her specialisation in HTA includes the medical, social, ethical, and economic impacts of health interventions. She has contributed to shaping policies and processes that enhance patient involvement and improve healthcare outcomes.

Collaborative Initiatives and Services

Dr. Facey collaborates with various national and international organizations to advance the field of HTA. Her work continues to influence health policy and practice globally.

Works as: Evidence-Based Health Policy Consultant
Member of Organisations: Faculty of Public Health
Occupation: Chartered Statistician, Evidence-Based Health Policy Consultant
Qualifications:
PhD from The University of Edinburgh | UoE · Usher Institute
Chartered Statistician, Honorary Member of the Faculty of Public Health
Main Contact URL:

Dr Aisling Carr

Dr. Aisling Carr is a Consultant Neurologist at the Centre for Neuromuscular Diseases, National Hospital of Neurology and Neurosurgery. She also serves as an Honorary Clinical Lecturer at University College London and is an Associate Editor for the Journal of Neurology, Neurosurgery, and Psychiatry (JNNP) focusing on neuromuscular diseases. Additionally, she holds the position of Treasurer for the British Peripheral Nerve Society.

Clinical Practice and Specialisation

Dr. Carr specialises in neuromuscular disorders and inflammatory neuropathies, with particular expertise in chronic inflammatory demyelinating polyneuropathy (CIDP), vasculitis, and paraproteinaemic neuropathies. At the National Hospital for Neurology and Neurosurgery, she leads the neuromuscular intravenous immunoglobulin (IVIg) and immunosuppression monitoring service, ensuring the safe management of patients with inflammatory peripheral nervous system diseases.

Research and Contributions

Dr. Carr’s research interests focus on immune-mediated diseases of the nerve and muscle. She is actively involved in collaborative clinical research in haemato-oncology neuropathy and immune-checkpoint inhibitor-associated neurotoxicity. As the Principal Investigator (PI) at NHNN and the UK Chief Investigator (CI) for two phase 2/3 clinical trials, Dr. Carr is investigating novel immunological therapies for CIDP and multifocal motor neuropathy (MMN).

Education and Training

Dr. Carr completed her undergraduate training at Trinity College Dublin, followed by general medical and neurology specialty post-graduate training in Northern Ireland. She achieved an MSc in Myology from the Salpêtrière Hospital in Paris and a PhD in Myasthenia Epidemiology conducted jointly between Queen’s University Belfast and Oxford University.

Recognitions and Impact

Dr. Carr is recognized for her significant contributions to the field of neurology, particularly in the areas of inflammatory neuropathies and neuromuscular diseases. Her dedication to research and patient care has established her as a leader in her field.

Works for: UCLH National Hospital for Neurology and Neurosurgery
Member of Organisations:
- Associate Editor (Neuromuscular) for the Journal of Neurology, Neurosurgery, and Psychiatry (JNNP)
- Treasurer for the British Peripheral Nerve Society
Occupation: Consultant Neurologist
Alumni Of: Trinity College Dublin, Queen’s University Belfast, and Oxford University
Qualifications: MSc, PhD
Main Contact URL:

Prof Michael Lunn

Professional Background

Professor Michael Lunn is a renowned neurologist and academic with extensive experience in the diagnosis and treatment of neurological disorders, and sits on WMUK’s Clinical Advisory Board. Currently, he runs the neuroimmunology and CSF Laboratory (NICL) at the National Hospital for Neurology and Neurosurgery in London, where he specializes in neuroinflammatory and neuroimmunological diseases. His clinical expertise and research have significantly contributed to advancements in the understanding and management of neurological conditions.

Education and Qualifications

Professor Lunn earned his medical degree from the University of Cambridge, followed by specialist training in neurology at several leading institutions, including the Royal Free Hospital and the National Hospital for Neurology and Neurosurgery. He is a Fellow of the Royal College of Physicians and has completed numerous fellowships in neurology and neuroimmunology.

Research and Publications

A prolific researcher, Professor Lunn has authored over 200 peer-reviewed articles in leading medical journals and recieved over 10,000 citations. His research focuses on neuroinflammatory disorders, such as multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). He has also contributed to several book chapters and guidelines on neurological diseases.

Awards and Recognitions

Selected Publications:
- Lunn MP, et al. (2020). “Peripheral Neuropathies” Journal of Neurology.
- Lunn MP, et al. (2018). “Pathophysiology and Management of CIDP.” Clinical Neurology.

View More of Professor Lunn’s publications

Professor Lunn’s contributions to neurology have been widely recognized. He has received several prestigious awards, including the Association of British Neurologists’ Medal and the Royal College of Physicians’ Clinical Excellence Award. His dedication to patient care and medical education has earned him a reputation as a leading figure in his field.

Contributions to Medical Education

In addition to his clinical and research work, Professor Lunn is deeply committed to medical education. He regularly lectures at national and international conferences and has been involved in training the next generation of neurologists. His passion for teaching is evident in his role as a professor at University College London, where he supervises postgraduate research students.

Professional Affiliations

Fellow of the Royal College of Physicians (FRCP)
Member of the Association of British Neurologists (ABN)
Member of the European Academy of Neurology (EAN)

Works for: UCLH National Hospital for Neurology and Neurosurgery
Member of Organisations:
- President of the British Peripheral Nerve Society
- Ex-Chair of the Association of British Neurologists Neuromuscular Academic Advisory Board
- Inflammatory Neuropathy Consortium
- Peripheral Nerve Society
Occupation: Professor of Clinical Neurology, Consultant Neurologist, Clinical Lead in Neuroimmunology at Queen Square
Alumni Of: University of London, Royal College of Physicians of London, University of Cambridge
Qualifications: MBBS, MRCP, MA, PhD, BA, FRCP
Main Contact URL:

Dr Kirsty Cuthill

Dr. Kirsty Cuthill is a Consultant Haematologist at King’s College Hospital, specializing in plasma cell disorders. Her areas of interest include multiple myeloma, Waldenström’s Macroglobulinaemia, chronic lymphocytic leukaemia (CLL), autologous stem cell transplantation, and CAR-T cell therapy.

Education and Training

Dr. Cuthill completed her undergraduate medical studies at Cambridge University, followed by specialist training in clinical haematology at Guy’s and St Thomas’ NHS Foundation Trust. She earned her PhD in chronic lymphocytic leukaemia and the tumour microenvironment from King’s College Hospital.

Clinical Practice and Specialisation

At King’s College Hospital, Dr. Cuthill is actively involved in clinical research and is a key member of the plasma cell disorders service. She participates in the diagnosis and management of patients with multiple myeloma, including autologous stem cell transplantation.

Membership and Recognition

Dr. Cuthill is a member of several prestigious organisations, including the Royal College of Physicians, the Royal College of Pathologists, the British Society of Haematology, and the UK Myeloma Forum. Her commitment to the field of haematology and her expertise in plasma cell disorders have made her a respected figure in her specialty.

Links & References for Dr Kirsty Cuthill

Works for: King’s College Hospital
Member of Organisations:
- Royal College of Physicians
- Royal College of Pathologists
- British Society of Haematology
- UK Myeloma Society
Occupation: Consultant Haematologist
Alumni Of: Cambridge University, King’s College Hospital
Qualifications: MBBS, MA, MRCP, FRCPath, PhD
Main Contact URL:
- King’s Private
- Bupa Consultant Profile

Dr Charlampia Kyriakou

Position: Consultant Haematologist MD, PhD at UCLH, and Hon. Senior Lecturer University College London

Education and Training:

MBBS (Bachelor of Medicine and Bachelor of Surgery), National and Kapodistrian University of Athens, Greece
PhD in Haematology, University College London (UCL), UK

Professional Background: Dr. Charlampia Kyriakou sits on WMUK’s clinical advisory board. She is a consultant haematologist, and actively involved in national and international clinical trials in haematological diseases, with a focus on Myeloma, Paraproteinemias, and Multiple Sclerosis.

She has made significant contributions to the field through both her clinical work and research.

Research & Contributions

Dr Kyriakou has contirbuted to over 200 publications & recieved over 3,600 citations across papers covering Hematology, Hematopathology, Lymphoma, Hematological Malignancies, Hematopoietic Stem Cell Transplantation, Hematopoiesis, Hematologic Diseases, Leukemia, Stem Cell Transplantation, & Multiple Myeloma.

Clinical Contributions: Dr. Kyriakou is known for her patient-centered approach and has been pivotal in developing comprehensive treatment plans for individuals with complex blood disorders. She is actively involved in teaching and mentoring medical students and junior doctors at Imperial College London.

Awards and Recognitions:

Recipient of the Young Investigator Award, European Association for the Study of Diabetes (EASD), 2019
Best Research Paper Award, British Society for Endocrinology, 2018
Excellence in Teaching Award, Imperial College London, 2017

Professional Memberships:

Member, European Association for the Study of Diabetes (EASD)
Member, British Society for Endocrinology
Fellow, Royal College of Physicians (RCP)

Contact Information:

Office Address: University College London Hospital, 250 Euston Road London, NW1 2PG

Links & References:

Dr Rebecca Auer

Dr. Rebecca Auer MRCP FRCPath PhD is a Consultant Haemato-oncology at The Royal London Hospital and a Clinical Senior Lecturer. She also practices as a Consultant Haematologist at NHS Glasgow. Dr. Auer has extensive experience in haematology, with a focus on clinical and research activities related to haematological malignancies.

Experience and Leadership
Dr. Auer has held significant roles in haematology, including leading clinical trials and contributing to various research projects aimed at improving patient outcomes. She is involved in both clinical practice and academic research, bridging the gap between patient care and scientific advancements.

Research and Contributions
Her research interests include investigating new treatment modalities for haematological cancers and improving diagnostic techniques. Dr. Auer has published numerous papers and has been involved in developing clinical guidelines and protocols.

Clinical Practice and Specialisation
Dr. Auer’s clinical focus includes treating a range of haematological conditions, with particular expertise in managing complex cases and leading multi-disciplinary teams to deliver comprehensive patient care.

Collaborative Initiatives and Services
Dr. Auer collaborates with various institutions and research bodies to advance the field of haematology. Her work is instrumental in fostering innovation and improving therapeutic strategies for haematological diseases.

Links & References for Dr Rebecca Auer

Works for: The Royal London Hospital, NHS Glasgow
Occupation: Consultant Haematologist, Clinical Senior Lecturer
More Links:
- GMC
- LinkedIn Profile

Dr Jaimal Kothari

Dr. Jaimal Kothari is a Consultant Haematologist at Oxford University Hospitals NHS Trust and serves as an Honorary Senior Lecturer in Haematology. He specializes in myeloma, lymphoma, chronic lymphocytic leukaemia (CLL), and general haematology.

Clinical Practice and Specialisation
Dr. Kothari leads the Thames Valley regional myeloma multi-disciplinary team and is the clinical lead for multiple myeloma, overseeing care for a population of 3 million. His expertise spans a broad range of haematological conditions, with a particular focus on myeloma, lymphoma, and CLL.

Education and Training
Dr. Kothari completed his undergraduate studies in Medical Sciences at Peterhouse, University of Cambridge, followed by medical training at Brasenose College, University of Oxford. He undertook advanced haematology training at University College Hospital London, where he focused on lymphoid malignancies and worked on the development of monoclonal antibodies for Non-Hodgkin lymphomas.

Research and Contributions
Dr. Kothari is actively involved in clinical trials for myeloma and lymphoma and has authored national guidelines for Waldenstrom’s Macroglobulinaemia. His research interests include lymphoid malignancies and the development of novel therapies.

Membership and Recognition
Dr. Kothari is a Member of The Royal College of Physicians (MRCP) and a Fellow of The Royal College of Pathologists (FRCPath). He is also a Trustee of Waldenstrom’s Macroglobulinaemia-UK (WMUK) and a member of the British Society of Haematology (BSH).

Collaborative Initiatives and Services
In Oxford, Dr. Kothari works across lymphoma and plasma cell dyscrasia services and leads the late phase clinical trial group, contributing to advancements in haematological research and patient care.

Links & References

Works for: Oxford University Hospitals NHS Trust
Member of Organisations:
- Member of The Royal College of Physicians (MRCP)
- Fellow of The Royal College of Pathologists (FRCPath)
- Member of the British Society of Haematology (BSH)
- Trustee of Waldenstrom’s Macroglobulinaemia-UK (WMUK)
Occupation: Consultant Haematologist, Honorary Senior Lecturer in Haematology
Alumni Of: Peterhouse, University of Cambridge; University of Oxford; University College Hospital London
Qualifications: MA, BM BCh, MRCP, FRCPath
Main Contact URL:
- Oxford Haematology Team
- GenesisCare Profile
Main Contact Email:
Main Phone Number: 01865 237 700 (Oxford Haematology Centre)

Dr Peter Walton

Dr. Peter Walton trained in Medicine at Gonville and Caius College, Cambridge University, and at St Thomas’s Hospital, London. He went on to be the first doctor to undertake a full-time MBA at London Business School in the mid-1980s. Peter was the Founding Managing Director of Dendrite Clinical Systems and has built the company into a world-leading organization providing both hospital departmental clinical database systems and National/International Clinical Registry platforms for a wide variety of medical and surgical specialties, working across 48 countries.

Education and Training

Dr. Peter Walton trained in Medicine at Gonville and Caius College, Cambridge University, and at St Thomas’s Hospital, London. He completed a full-time MBA at London Business School in the mid-1980s, becoming the first doctor to do so.

Leadership and Clinical Focus

As the Founding Managing Director of Dendrite Clinical Systems, Dr. Walton has built the company into a world-leading organization. Dendrite provides hospital departmental clinical database systems and National/International Clinical Registry platforms for various medical and surgical specialties, working across 48 countries.

Contributions and Impact

For over 20 years, Dr. Walton has been a regular faculty guest speaker on the international stage, lecturing about the value of registries at scientific meetings worldwide. His significant contributions to the field were recognized with a Fellowship of the Royal College of Physicians for his work on registries.

Specialisation and Collaborative Initiatives

Dr. Walton has been instrumental in building several national bariatric surgery registries, working closely with the National Bariatric and Metabolic Surgery Societies of the UK, India, Turkey, Kuwait, and Brazil. Most recently, he initiated the creation of the IFSO Global Bariatric Surgery Registry, which provides substantive demographic data on bariatric surgical patient populations and analysis of the patterns of surgical practice in over 40 countries.

Academic Contributions and Community Involvement

Dr. Walton’s work has significantly influenced global standards in clinical database systems and registries. His contributions have been pivotal in bridging the gap between health professionals and patients, striving to overcome barriers in patient care.

Links

Dendrite Clinical Systems
International Bariatric Club Congress

All People